Aquigen Bio Science

Executive Summary

Aquigen Bio Science is an Indian contract research and manufacturing organization (CRMO) specializing in high-purity pharmaceutical reference standards, impurity standards, deuterated labeled compounds, and custom synthesis of APIs and intermediates. Founded in 2020 and based in Hyderabad, the company serves the pharmaceutical, biologics, nutraceutical, agrochemical, and cosmetics sectors. Its advanced synthetic chemistry and analytical capabilities enable it to support drug discovery and development programs with regulatory-compliant materials, thereby accelerating the path to market for clients. With a lean team of 50–200 employees, Aquigen has positioned itself as a reliable partner for pharma companies seeking quality research-grade substances and analytical services. Looking ahead, Aquigen is well-placed to capitalize on the growing demand for high-purity reference standards and deuterated compounds, driven by increasing regulatory scrutiny and the need for precise analytical data. The company's focus on custom synthesis and niche capabilities such as stable isotope labeling could differentiate it from larger competitors. However, as a relatively young and privately held CRMO, its growth is contingent on continued investment in infrastructure and talent. The company's platform stage and lack of disclosed funding suggest a need for strategic partnerships or client wins to scale. With a solid foundation in a supportive Indian biotech ecosystem, Aquigen has moderate potential for steady expansion.

Upcoming Catalysts (preview)

• Q2 2026Major GMP Certification or Regulatory Audit Success80% success
• Q4 2026Strategic Partnership with Top 20 Pharma Company for Custom Synthesis40% success
• Q3 2026Expansion of Deuterated Compound Manufacturing Capacity70% success